CDC Chief Says Omicron Cases in US Mostly Mild So Far

More than 40 people in the U.S. have been found to be infected with the omicron variant so far, and more than three-quarters of them had been vaccinated, the chief of the CDC said Wednesday. But she said nearly all of them were only mildly ill.

In an interview with The Associated Press, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said the data is very limited and the agency is working on a more detailed analysis of what the new mutant form of the coronavirus might hold for the United States.

“What we generally know is the more mutations a variant has, the higher level you need your immunity to be. … We want to make sure we bolster everybody’s immunity. And that’s really what motivated the decision to expand our guidance,” Walensky said, referencing the recent approval of boosters for all adults.

She said “the disease is mild” in almost all of the cases seen so far, with reported symptoms mainly cough, congestion and fatigue. One person was hospitalized, but no deaths have been reported, CDC officials said.

Some cases can become increasingly severe as days and weeks pass, and Walensky noted that the data is a very early, first glimpse of U.S. omicron infections. The earliest onset of symptoms of any of the first 40 or so cases was November 15, according to the CDC.

The omicron variant was first identified in South Africa last month and has since been reported in 57 countries, according to the World Health Organization.

The first U.S. case was reported on December 1. As of Wednesday afternoon, the CDC had recorded 43 cases in 19 states. Most were young adults. About a third of those patients had traveled internationally.

More than three-quarters of those patients had been vaccinated, and a third had boosters, Walensky said. Boosters take about two weeks to reach full effect, and some of the patients had received their most recent shot within that period, CDC officials said.

Fewer than 1% of the U.S. COVID-19 cases genetically sequenced last week were the omicron variant; the delta variant accounted for more than 99%.

Scientists are trying to better understand how easily it spreads. British officials said Wednesday that they think the omicron variant could become the dominant version of the coronavirus in the United Kingdom in as soon as a month.

The CDC has yet to make any projections on how the variant could affect the course of the pandemic in the U.S. Walensky said officials are gathering data, but many factors could influence how the pandemic evolves.

“When I look to what the future holds, so much of that is definitely about the science, but it’s also about coming together as a community to do things that prevent disease in yourself and one another. And I think a lot of what our future holds depends on how we come together to do that,” she said.

The CDC is also trying to establish whether the omicron variant causes milder — or more severe — illness than other coronavirus types. The finding that nearly all of the cases so far are mild may be a reflection that this first look at U.S. omicron cases captured mainly vaccinated people, who are expected to have milder illnesses, CDC officials said.

Another key question is whether it is better at evading vaccines or the immunity people build from a bout with COVID-19.

This week, scientists in South Africa reported a small laboratory study that found antibodies created by vaccines were not as effective at preventing omicron infections as they were at stopping other versions of the coronavirus.

On Wednesday, vaccine manufacturer Pfizer said that while two doses may not be protective enough to prevent infection, lab tests showed a booster increased levels of virus-fighting antibodies by 25-fold.

Blood samples taken a month after a booster showed people harbored levels of omicron-neutralizing antibodies that were similar to amounts proven protective against earlier variants after two doses, the company said.

Source: Voice of America

Mining Opportunities and Infrastructure in Southern Africa 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Mining in Southern Africa 2021” report has been added to ResearchAndMarkets.com’s offering.

Southern Africa has produced a large number of minerals, including over 25% of the world’s diamonds, over 13% of its graphite and 10% of its uranium. The region contains deposits of a range of minerals, many of which are not exploited. Dozens of companies are actively exploring in the region, but challenges include a lack of skilled workers and inadequate infrastructure. While a large number of companies are involved in mining in Southern Africa, artisanal mining forms a large part of the industry.

Opportunities

Southern Africa’s mining industry is benefiting from rising demand for a variety of minerals as the world economy recovers. Most countries in the region have identified mining as important for economic development and are trying to develop their mining sectors. With many deposits unexploited and rising demand for various minerals, there is potential for the development of new mines.

Infrastructure

In some countries, economic development is hindered by the lack and poor condition of transport, water, electricity and telecommunication infrastructure, while transportation costs are increased by poor road infrastructure due to long distances travelled at low speeds. The logistics of delivering heavy equipment and materials to build a mine in remote areas, where the road systems are poor, pose a challenge to mining companies. Inadequate electricity supply is a serious problem, with the provision of alternative energy sources adding to companies’ costs.

Report Coverage

This report focuses on mining in Angola, Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia and Zimbabwe, which constitute the African Union’s Southern Africa region. It includes comprehensive information on mineral occurrences, developments and corporate actions as well as the state and size of the sector, trade and regulations.

There are profiles of 43 companies including Debswana and Mupane Gold Mining in Botswana, Zimbabwe Platinum Mines, Swakop Uranium and Namdeb in Namibia, Montepuez Ruby Mining in Mozambique and Lubambe Copper Mine in Zambia.

Key Topics Covered:

1. INTRODUCTION

2. REGION INFORMATION

3. DESCRIPTION OF THE INDUSTRY

3.1. Industry Value Chain

3.2. Geographic Position

4. SIZE OF THE INDUSTRY

5. STATE OF THE INDUSTRY

5.1. Local

5.1.1. Trade

5.1.2. Corporate Actions

5.1.3. Regulations

5.2. Continental

5.3. International

6. INFLUENCING FACTORS

6.1. Coronavirus

6.2. Economic Environment

6.3. Lack of Infrastructure

6.4. Technology, Research and Development (R&D) and Innovation

6.5. Government Incentives and Support

6.6. Environmental Concerns

6.7. Labour

7. COMPETITION

7.1. Barriers to Entry

8. SWOT ANALYSIS

9. OUTLOOK

10. INDUSTRY ASSOCIATIONS

COMPANY PROFILES

• African Chrome Fields (Pvt) Ltd

• AfriTin Mining Ltd

• B2Gold Namibia (Pty) Ltd

• Bikita Minerals (Pvt) Ltd

• Bindura Nickel Corporation Ltd

• Chibuluma Mines PLC

• CNMC Luanshya Copper Mines PLC

• Companhia Siderurgica do Cuchi S.A.

• Consolidated Nickel Mines Ltd

• De Beers Marine Namibia (Pty) Ltd

• Debswana Diamond Company (Pty) Ltd

• Empresa Nacional de Diamantes de Angola EP

• Great Dyke Investments (Pvt) Ltd

• Hwange Colliery Company Ltd

• Kagem Mining Ltd

• Kansanshi Mining PLC

• Khoemacau Copper Mining (Pty) Ltd

• Letseng Diamonds (Pty) Ltd

• Lodestone Namibia (Pty) Ltd

• Lubambe Copper Mine PLC

• Lucara Diamond Corp.

• Lumwana Mining Company Ltd

• Maamba Collieries Ltd

• Makomo Resources (Pvt) Ltd

• Maloma Colliery Ltd

• Mimosa Mining Company (Pvt) Ltd

• Minergy Ltd

• Morupule Coal Mine (Pty) Ltd

• Mupane Gold Mining (Pty) Ltd

• Namdeb Diamond Corporation (Pty) Ltd

• NFC Africa Mining PLC

• Prospect Resources Ltd

• RioZim ltd

• Rosh Pinah Zinc Corporation (Pty) Ltd

• Rossing Uranium Ltd

• Storm Mountain Diamonds (Pty) Ltd

• Swakop Uranium (Pty) Ltd

• Unki Mines (Pvt) Ltd

• Zimasco (Pvt) Ltd

• Zimbabwe Platinum Mines (Pvt) Ltd

For more information about this report visit https://www.researchandmarkets.com/r/xc8h7b

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Source: Business Wire

US Authorizes AstraZeneca COVID Drug for a Few Who Can’t be Vaccinated

U.S. health authorities on Wednesday authorized the use of synthetic antibodies developed by AstraZeneca to prevent COVID-19 infections in people who react badly to vaccines.

It was the first time the Food and Drug Administration has given emergency authorization for such a purely preventative treatment.

The FDA warned the drug Evusheld is “not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended” and can only be authorized for people with weakened immune systems or those who cannot be vaccinated for medical reasons, such a strong allergic reaction.

In those cases, the drug can be administered to people 12 and older.

Evusheld combines two types of synthetic antibodies (tixagevimab and cilgavimab), and is given as two intramuscular injections, one right after the other. These antibodies help the immune system fight off the virus by targeting its spike protein, which allows it to enter cells and infect them.

The FDA said that the treatment “may be effective for pre-exposure prevention for six months.”

It cannot be administered to someone who is already infected with the virus, the FDA said, although AstraZeneca is testing it for such treatment.

Side effects may include an allergic reaction, bleeding from the injection site, headache, and fatigue.

The FDA authorization was based on a clinical trial carried out on unvaccinated people older than 59, or with a chronic disease, or at high risk of infection.

The drug was given to 3,500 people while 1,700 received a placebo. The trial showed that the treatment cut the risk of developing COVID-19 by 77%.

Two cocktails of antibodies, made by Regeneron and Eli Lilly, are currently authorized for prevention of infection in the United States, but only in people who have been exposed to the virus shortly before, or who have a strong chance of being exposed, such as employees of retirement homes or prisons.

In addition to being immunocompromised or unvaccinated, these people must also be at high risk of developing a severe case of the disease.

Source: Voice of America

COVID-19 pandemic slows progress against tuberculosis

Brazzaville, 8 December 2021 –The COVID-19 pandemic’s disruption to health services has seen an increase in tuberculosis deaths in Africa, the first such rise in more than a decade, while the decline in new cases slowed down, an analysis by World Health Organization (WHO) shows.

The African region has made progress against tuberculosis, reducing cases by 19% between 2015 and 2020—reflecting a decline of 4–10% per year in South Africa and several other in southern Africa countries. However, the region reported 549 000 deaths in 2020, an increase of around 2000 over 2019 and while cases fell modestly by 2.5% in 2020 from 1.4 million the previous year, there were significant drops in reporting of new infections in countries with high tuberculosis burden including Angola, South Africa and Zimbabwe—all of which have grappled with high COVID-19 cases.

Reallocation of resources and health workforce to tackle COVID-19 in many African countries as well as drastic pandemic response measures such as lockdowns greatly reduced access to key health services including tuberculosis diagnosis and treatment. The African region is home to 17 of the 30 countries globally that have the highest burden of tuberculosis and the trend seen in the region follows a rise in tuberculosis cases worldwide due to the COVID-19 impact

“The pandemic has put progress against tuberculosis on the line,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “Although times are hard and efforts strained by the race to overcome COVID-19, African governments must work harder now to revamp and improve access to essential health services.”

The African region had made progress in reducing tuberculosis cases

The WHO End Tuberculosis Strategy sets key targets to end the disease. Countries should aim for a 90% reduction in tuberculosis deaths and an 80% reduction in case by 2030 compared with 2015. The strategy outlines key milestones for countries to reach by 2020 and 2025.

The 2020 milestone seeks a 35% reduction in tuberculosis deaths and 20% decline in cases. A WHO scorecard released today on the 2020 milestone finds that only eight countries—Botswana, Cabo Verde, Eswatini, Ethiopia, Kenya, Namibia, South Africa and Togo—met or exceeded the 20% reduction target.

Thirteen countries achieved the target to reduce deaths by 35% in 2020, according to the scorecard. However, the analysis also found that there were significant data gaps in key areas due in part to the challenges posed by the pandemic. Although most countries do not report data on tuberculosis preventive treatment especially for people living with HIV, five countries namely—Kenya, Malawi, Nigeria, Uganda, Zimbabwe—exceeded the target.

The scorecard also measures the proportion of households experiencing catastrophic costs due to tuberculosis. Patients and their households can face severe direct and indirect financial and economic costs that pose barriers that can greatly affect their access to diagnosis and treatment. Eight countries completed the tuberculosis cost surveys for 2020. No country has yet demonstrated that it has met the target that no tuberculosis-affected households face catastrophic costs.

Tuberculosis is the leading killer of people with HIV and the African region has the highest burden of HIV-associated tuberculosis. Factors including insufficient funding for programmes, limited access to modern diagnostic tools as well as low implementation of preventive treatment hinder progress against the disease.

Addressing factors such as poor living and working conditions as well as risk factors including HIV infection, malnutrition, diabetes, smoking and alcohol abuse have the potential to drive down the tuberculosis epidemic. This is possible through collaborative efforts involving the health sector, other government bodies, the private sector, non-governmental organizations donors and communities.

“Reining in this preventable, curable disease calls for matching resources to political will. We need to increase investment in diagnosis and treatment to get back on track,” Dr Moeti said.

Despite the challenges, there has been progress on other key indicators. For instance, most African countries have met or exceeded the goal of providing at least 90% of HIV-positive tuberculosis patients with antiretroviral treatment during their treatment for tuberculosis. In five countries—Burundi, Mauritius, Sao Tome and Principe, Seychelles and Sierra Leone—100% of HIV-positive tuberculosis patients were reported as having started or continued antiretroviral treatment while being treated for tuberculosis.

Additionally, treatment success rate for new and relapse cases have also surpassed 90% in Burundi, the Democratic Republic of the Congo, Eritrea, Ethiopia, Mozambique, Senegal and Tanzania.

Source: World Health Organization

WHO South Sudan conducts a consultation meeting with the Ministry of Health to review the draft 2022-2023 biennium plan.

-The World Health Organization (WHO) South Sudan Country Office held a consultative meeting with the senior management of the Ministry of Health on 6 November 2021. The aim of the meeting was to align WHO workplans for 2022-2023 biennium with country priorities.

WHO plans in two-year cycles (biennium) with the current biennial plan 2020-2021 ending on 31 December 2021.

The meeting was officiated by Dr Fabian Ndenzako, the WHO Representative a.i. for South Sudan and Dr Paul Samson Baba, Acting Undersecretary of the Ministry of Health. In attendance were Directors General and other top officials from the Ministry of Health as well as WHO Country office technical staff.

During his opening remarks, Dr Ndenzako underscored the need for enhanced teamwork and effective coordination between the Ministry and health stakeholders including WHO to improve the health security for all people in South Sudan.

“WHO is here to support the Ministry of Health, and this consultation meeting provides an opportunity to reflect on how WHO and the Ministry of Health can work together more effectively to improve the health outcomes of the people in South Sudan.” Said Dr Ndenzako.

According to Dr Paul Samson Baba, Acting Undersecretary at the Ministry of Health, the technical support, and guidance that WHO has been providing has led to the country registering some positive health outcomes including responding to numerous emergencies with public health consequences and in a fragile, conflict-affected, and compounded with severe food insecurity, floods, and disease outbreaks.

“We are thankful to WHO for this constructive engagement aimed at aligning WHO workplans with country priorities towards improving health and wellbeing of the people of South Sudan,” said Dr Baba. “Now our priorities are clearly spelt out and we are headed for implementation and with this spirit of teamwork I am hopeful we shall achieve more in the upcoming biennium.”

WHO South Sudan and the Ministry will continue to refine the plan to make it the most adjusted and fit for purpose, in line with the Republic of South Sudan Health-related objectives.

The World Health Organization is the key United Nations agency that connects nations, partners and people to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere can attain the highest level of health.

For the WHO to deliver better results, the organization applies a result-based management framework. WHO’s results-based management framework is informed by the vision and strategic direction set in the General Programme of Work (GPW) 13. The full cycle is completed by the monitoring and evaluation to assess the achievement of results and applying these results to re-plan in a continuous organizational learning manner.

Source: World Health Organization. Africa

California Plans to Be Abortion Sanctuary if Roe Overturned

With more than two dozen states poised to ban abortion if the U.S. Supreme Court gives them the OK next year, California clinics and their allies in the state legislature on Wednesday revealed a plan to make the state a safe place for those seeking reproductive care, including possibly paying for travel, lodging and procedures for people from other states.

The California Future of Abortion Council, made up of more than 40 abortion providers and advocacy groups, released a list of 45 recommendations for the state to consider if the high court overturns Roe v. Wade, the 48-year-old decision that forbids states from outlawing abortion.

The recommendations are not just a liberal fantasy. Some of the state’s most important policymakers helped write them, including Toni Atkins, the San Diego Democrat who leads the state Senate and attended multiple meetings.

Democratic Governor Gavin Newsom started the group himself. In an interview last week with The Associated Press he said some of the report’s details would be included in his budget proposal in January.

“We’ll be a sanctuary,” Newsom said, adding he’s aware patients will likely travel to California from other states to seek abortions. “We are looking at ways to support that inevitability and looking at ways to expand our protections.”

California already pays for abortions for many low-income residents through the state’s Medicaid program. And California is one of six states that require private insurance companies to cover abortions, although many patients still end up paying deductibles and co-payments.

Enough money

But money won’t be a problem for state-funded abortion services for patients from other states. California’s coffers have soared throughout the pandemic, fueling a record budget surplus this year. Next year, the state’s independent Legislative Analyst’s Office predicts California will have a surplus of about $31 billion.

California’s affiliates of Planned Parenthood, the nation’s largest abortion provider, got a preview of how people might seek abortions outside their home states this year when a Texas law that outlawed abortion after six weeks of pregnancy was allowed to take effect. California clinics reported a slight increase in patients from Texas.

Now, California abortion providers are asking California to make it easier for those people to get to the state.

The report recommends funding — including public spending — to support patients seeking abortion for travel expenses such as gas, lodging, transportation and child care. It asks lawmakers to reimburse abortion providers for services to those who can’t afford to pay — including those who travel to California from other states whose income is low enough that they would qualify for state-funded abortions under Medicaid if they lived there.

It’s unclear how many people would come to California for abortions if Roe v. Wade is overturned. California does not collect or report abortion statistics. The Guttmacher Institute, a research group that supports abortion rights, said 132,680 abortions were performed in California in 2017, or about 15% of all abortions nationally. That number includes people from out of state as well as teenagers, who are not required to have their parents’ permission for an abortion in California.

Planned Parenthood, which accounts for about half of California’s abortion clinics, said it served 7,000 people from other states last year.

A huge influx of people from other states “will definitely destabilize the abortion provider network,” said Fabiola Carrion, interim director for reproductive and sexual health at the national Health Law Program. She said out-of-state abortions would also likely be later-term procedures, which are more complicated and expensive.

More workers

The report asks lawmakers to help clinics increase their workforce to prepare for more patients by giving scholarships to medical students who pledge to offer abortion services in rural areas, help them pay off their student loans and assist with their monthly liability insurance premiums.

“We’re looking at how to build capacity and build workforce,” said Jodi Hicks, CEO of Planned Parenthood Affiliates of California. “It will take a partnership and investment with the state.”

Abortion opponents in California, meanwhile, are also preparing for a potential surge of patients from other states seeking the procedure — only they hope to persuade them not to do it.

Jonathan Keller, president and CEO of the California Family Council, said California has about 160 pregnancy resource centers whose aim is to persuade women not to get abortions. He said about half of those centers are medical clinics, while the rest are faith-based counseling centers.

Many of the centers are located near abortion clinics in an attempt to entice people to seek their counseling before opting to end pregnancies. Keller said many are already planning on increasing their staffing if California gets more patients.

“Even if we are not facing any immediate legislative opportunities or legislative victories, it’s a reminder that the work of changing hearts and minds and also providing real support and resources to women facing unplanned pregnancies — that work will always continue,” Keller said.

He added: “In many ways, that work is going to be even more important, both in light of [the] Supreme Court’s decision and in light of whatever Sacramento decides they are going to do in response.”

Source: Voice of America